Diabetic eye disease: The urgent need for early, non-invasive treatments
Drug Discovery World
MAY 15, 2024
Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Specific numerical values (steps) denote the severity of NPDR, with 47-53 describing the moderately severe disease.
163 
Let's personalize your content